ERBB2 and colorectal carcinoma: Since HER2 exhibited significantly increased levels in mCRC as compared with primary CRC (Fig. 2C, D), CRC PDX models showed that HER2 CAR-T displayed great aggressiveness in HER2+ CRC (Fig. 5), and HER2 CAR-T cells were associated with the suppression of distant metastases in CRC (Fig. 4F) in order to investigate the therapeutic capacity of HER2 CAR-T cells for mCRC, a PDX metastasis model of CRC was developed.